排名前五的靶点	数量

CDK7(细胞周期蛋白依赖性激酶7)	3
USP1(ubiquitin specific peptidase 1)	3
PHD2(egl-9 family hypoxia inducible factor 1)	3
QPCTL(glutaminyl-peptide cyclotransferase like)	2
ENPP1(核苷酸内焦磷酸酶/磷酸二酯酶1)	2

关联

项与英矽智能(香港)有限公司相关的药物

Triamterene

氨苯蝶啶

靶点

ENaC

作用机制

ENaC阻滞剂

在研机构

InSilico Medicine, Inc. [+2]

原研机构

Concordia NV

在研适应症

水肿 [+3]

非在研适应症-

最高研发阶段批准上市

首次获批国家/地区

日本

首次获批日期1962-12-19

Rentosertib

靶点

TNIK

作用机制

TNIK抑制剂

在研机构

原研机构

在研适应症

非在研适应症-

最高研发阶段临床2期

首次获批国家/地区-

首次获批日期-

ISM-3091

靶点

USP1

作用机制

USP1抑制剂

在研机构

英矽智能科技（上海）有限公司 [+3]

原研机构

英矽智能(香港)有限公司

在研适应症

晚期恶性实体瘤 [+2]

非在研适应症-

最高研发阶段临床1期

首次获批国家/地区-

首次获批日期-

项与英矽智能(香港)有限公司相关的临床试验

NCT06724042

/ Not yet recruiting临床1期

First-in-human Phase 1a/b, Open-Label, Multicenter, Dose Escalation, Optimization and Expansion Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors

This is a first-in-human Phase 1a/b, open-label, multicenter, dose escalation, optimization and expansion study of ISM5939 to evaluate the safety, tolerability, PK, PD, and preliminary antitumor activity of ISM5939 in patients with advanced or metastatic solid tumors.
The study will be conducted in 3 parts sequentially: Part 1 dose escalation ISM5939 monotherapy, Part 2 dose optimization to determine RP2D of ISM5939 monotherapy, and Part 3 dose expansion in 3 cohorts after initial safety run-in of ISM5939 combination therapy.

开始日期2025-12-30

申办/合作机构

英矽智能(香港)有限公司

NCT06414460

/ Recruiting临床1期

A Phase 1, Open-Label, Multicenter, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Preliminary Efficacy of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors

The study has consists of two parts, a dose escalation part (Part 1) and a dose selection optimization part (Part 2). The primary objectives of this study are to evaluate the safety and tolerability of ISM3412 in participants with locally advanced/metastatic solid tumors, and to determine the RP2D of ISM3412.

开始日期2025-04-25

申办/合作机构

英矽智能(香港)有限公司

NCT06566079

/ Recruiting临床1期

A Phase 1, Open-Label, Multicenter, FIH Study to Evaluate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Preliminary Efficacy of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors

This is a Phase 1, open-label, multicenter, FIH study to evaluate the safety, tolerability, recommended Phase 2 dose (RP2D), PK/PD, and preliminary anti-tumor activity of ISM6331 in participants with advanced or metastatic malignant mesothelioma or other solid tumors. The study consists of two parts, a dose escalation part (Part 1) and a dose selection optimization part (Part 2).

开始日期2024-12-27

申办/合作机构

英矽智能(香港)有限公司

100 项与英矽智能(香港)有限公司相关的临床结果

登录后查看更多信息

0 项与英矽智能(香港)有限公司相关的专利（医药）

登录后查看更多信息

100

项与英矽智能(香港)有限公司相关的文献（医药）

2025-08-11·MATHEMATICAL MEDICINE AND BIOLOGY-A JOURNAL OF THE IMA

Some results about the structural properties of the Wnt pathway, its steady states and its non-associative commutative algebra.

Article

作者: Vanhaelen, Quentin

We consider a reaction network of the Wnt pathway endowed with mass-action kinetics. Using concepts in the theory of robustness and stability within Chemical Reaction Network Theory and advances in decomposing reaction networks, we perform a systematic analysis of the structural, structo-kinetic and kinetic properties of this pathway. We show that the network can be systematically decomposed into a set of subnetworks and we use elements matrix theory to study their stability properties. Considering the positive stoichiometric classes, we obtain the analytical expressions of the positive steady states and we identify three species with absolute concentration robustness within the core of the destruction complex of the pathway. We identify nonnegative stoichiometric classes which admit boundary steady states. We construct the non-associative commutative algebra associated with the system and combine algebraic and algorithmic approaches to characterize its structural properties, construct its subalgebras, and show how they relate to the existence of boundary initial conditions which admit boundary steady state solutions. We also show the existence of a category of subalgebras which generate unbounded solutions for most of the nonnegative initial conditions.

2025-08-08·Aging-US

AI-driven toolset for IPF and aging research associates lung fibrosis with accelerated aging.

Article

作者: Ren, Feng ; Zhavoronkov, Alex ; Aliper, Alex ; Galkin, Fedor ; Chen, Shan

Idiopathic pulmonary fibrosis (IPF) is a condition predominantly affecting the elderly and leading to a decline in lung function. Our study investigates the aging-related mechanisms in IPF using artificial intelligence (AI) approaches. We developed a pathway-aware proteomic aging clock using UK Biobank data and applied it alongside a specialized version of Precious3GPT (ipf-P3GPT) to demonstrate an AI-driven mode of IPF research. The aging clock shows great performance in cross-validation (R²=0.84) and its utility is validated in an independent dataset to show that severe cases of COVID-19 are associated with an increased aging rate. Computational analysis using ipf-P3GPT revealed distinct but overlapping molecular signatures between aging and IPF, suggesting that IPF represents a dysregulation rather than mere acceleration of normal aging processes. Our findings establish novel connections between aging biology and IPF pathogenesis while demonstrating the potential of AI-guided approaches in therapeutic development for age-related diseases.

2025-07-10·ACS Medicinal Chemistry Letters

Identification of Novel pan-KRAS Inhibitors via Structure-Based Drug Design, Scaffold Hopping, and Biological Evaluation

Article

作者: Mantsyzov, Alexey B. ; Cai, Xin ; Kruse, Chris ; Ding, Xiao ; Aladinskiy, Vladimir ; Shi, Sujing ; Noev, Alexey ; Reshetnikov, Viktor ; Ren, Feng ; Aliper, Alex ; Petrov, Rostislav ; Zhavoronkov, Alex

KRAS is one of the most frequently mutated oncogenes in human cancers. Discovery of the allosteric binding sites next to the switch II loop triggered the successful development of KRAS-targeting therapeutic agents featuring different modalities. pan-KRAS inhibitors are of particular interest due to the broader scope of clinical indications and potential to overcome certain types of emerging resistance typical of allele-specific KRAS modulators. Herein, we explore the chemical space around MRTX1133, a compound with selectivity toward the KRAS^G12D variant, aiming to find new chemotypes with the potential to derive a clinical candidate. A series of novel pan-KRAS inhibitors with a potency in the upper nanomolar range have been developed. The inhibitory activity was demonstrated against key oncogenic KRAS mutants and a wild-type protein.

1,060

项与英矽智能(香港)有限公司相关的新闻（医药）

2025-08-14

·英矽智能

衰老 | 英矽智能利用人工智能工具揭示特发性肺纤维化与加速衰老的关联

特发性肺纤维化（IPF）‌是一种‌慢性、进行性‌的肺部疾病，主要表现为‌肺部正常组织逐渐被瘢痕（纤维化）替代‌，导致肺功能不可逆性下降，最终引发呼吸衰竭。IPF主要影响60岁以上的人群，被认为与衰老过程存在共同的生物学路径。理解这些共同机制对于开发具有惠及全球的创新抗衰老治疗方案至关重要。近日，英矽智能（Insilico Medicine）的研究团队在《衰老》(Aging-US)期刊上发表了一项研究，利用人工智能（AI）方法探讨了IPF中与衰老相关的生物学机制。该研究建立了衰老生物学与IPF发病机制之间的新联系，同时展示了AI驱动的方法在研究与衰老相关疾病疗法开发中的巨大潜力。为推进该研究，团队开发了两种专门的深度学习模型：纤维化感知衰老时钟（fibrosis-aware aging clock），这是一种利用英国生物样本库（UK Biobank）蛋白组数据训练的聚焦于通路的蛋白组学衰老时钟；以及IPF-Precious3GPT，这是一种可根据文本提示生成基因差异表达谱的组学Transformer模型。用于研究IPF和纤维化疾病的深度学习模型其中，衰老时钟在交叉验证中表现出色，能够以高精度预测生物年龄（R²=0.84，均方误差MAE=2.68年）。研究人员随后将该模型应用于Olink蛋白组数据集，并采用线性回归方法评估疾病严重程度对衰老速度的影响。结果显示，患有重症感染并可能发展为肺纤维化的患者，其预测的生物年龄明显高于健康对照组，提示该时钟在纤维化病例中具有判断生物学年龄变化趋势的意义。此外，通过IPF-P3GPT生成模型的分析，研究人员发现衰老和肺纤维化疾病在基因表达方面既有共同特征，也存在独特模式，表明IPF不仅加速衰老，还包含独特的病理过程。研究进一步确定了四条关键通路（TGF-β信号通路、氧化应激、炎症和细胞外基质重塑）在IPF与衰老中均起核心作用，但在基因层面的参与方式有所不同。下一步，英矽智能的研究团队将通过专门的IPF患者队列验证AI模型，并将其方法扩展到其他纤维化以及衰老相关疾病研究领域。团队还计划将这些工具用于药物发现、生物标志物鉴定以及在衰老和慢性疾病领域个性化疗法策略的开发。凭借先进的AI与自动化技术，英矽智能大幅提升了药物研发前期的效率，并建立了AI驱动药物研发的标杆。与传统早期药物发现通常需耗时2.5至4年相比，英矽智能已完成20个临床前候选药物提名，每个项目从启动至候选药物确定的平均周期仅为12至18个月，且每个项目仅需合成和测试60至200个分子。自2014年成立以来，英矽智能已发表超过200篇同行评议论文。依托于在跨生物技术、人工智能和自动化领域的学术分享与持续突破，公司入选自然指数（Nature Index）2025科研领袖：全球生命科学与自然科学论文全球百强企业。 [1] Galkin F, Chen S, Aliper A, Zhavoronkov A, Ren F. AI-driven toolset for IPF and aging research associates lung fibrosis with accelerated aging. Aging (Albany NY). 2025 Aug 8; . https://doi.org/10.18632/aging.206295 关于英矽智能英矽智能是一家由生成式人工智能驱动的全球先锋生物科技公司，利用其专有的 Pharma.AI 平台和先进的自动化实验室，加速药物发现并推动生命科学领域的创新。通过整合人工智能和自动化技术，英矽智能正在为纤维化、肿瘤学、免疫学、疼痛、肥胖和代谢紊乱等未满足的疾病领域提供创新药物解决方案。英矽智能由人工智能驱动发现的产品管线中，已有10个分子获得临床试验许可，其中进展最为领先的Rentosertib（原名ISM001-055）是一种潜在全球首创用于治疗特发性肺纤维化的候选药物，已完成2a期临床研究并获得令人鼓舞的积极结果。此外，英矽智能还在探索前沿领域，包括老龄化研究、可持续化学和农业创新方面的突破。更多信息，请访问网站www.insilico.com 商务合作，请联系 bd@insilico.ai 媒体垂询，请联系 pr@insilico.ai

临床研究申请上市优先审批临床结果

2025-08-13

·BioBAY

《苏州日报》头版：全国新增创新药五分之一在园区

今天《苏州日报》头版关注园区 ↓↓↓ 全国新增创新药五分之一在园区今年以来已有6款上市创新策源效应不断凸显全文如下以政策的精准扶持加速技术迈向创新策源，以资本深度赋能驱动产业集群的聚变，今年以来，苏州工业园区“一号产业”能级加速提升。记者从园区科技创新委员会了解到，今年，园区已有6款一类创新药获批上市，约占全国同期新增量的20%，生物医药“创新策源”效应不断凸显。自2006年起园区就重点布局生物医药及大健康产业着力集聚创新资源要素至今已吸引相关企业超2000家 2024年实现产值1655亿元今年，紧扣“建设开放创新的世界一流高科技园区”目标，园区出台实施《生物医药及大健康产业腾飞行动计划（2025-2027）》《生物制造产业高质量发展行动计划》等政策，精准赋能产业体系升级。《生物医药及大健康产业腾飞行动计划》提出“5511”目标即到2027年培育5家国际龙头企业、50家细分领域领军企业、100个年销售额超亿元重磅产品、100个获批上市重点管线。政策通过“基石投资+长期持股”模式引导国资基金支持企业融资，目标未来三年引入上级资金超50亿元，并创新“管线贷”风险补偿机制，为研发型企业提供中长期信贷支持，通过多元化金融支持破解研发投入大、周期长的行业痛点。园区今年生物医药领域创新成果呈现爆发式增长共有6款一类创新药获批上市约占全国同期新增量的20% 覆盖肿瘤、代谢疾病等民生领域 ↓↓↓ • 亚盛医药的利生妥（Bcl-2选择性抑制剂）为国内首个治疗慢性淋巴细胞白血病的创新药。 • 信达生物的信尔美是全球首个GCG/GLP-1双受体激动减重药物； • 盛迪亚的艾维达为国内首款HER2突变非小细胞肺癌ADC药物，展现国产创新药国际竞争力。如今，在全球健康版图中 “园区力量”持续彰显资本市场的活跃表现更印证了这一实力 ↓↓↓ • 上半年，赛分科技登陆科创板，亚盛医药纳斯达克上市，维昇药业港股挂牌，形成“境内+境外”资本双轮驱动。 • 帕母医疗、英矽智能、爱科诺、嘉树医疗等创新企业完成新一轮近亿元以及过亿元融资。以人工智能深度渗透重塑研发范式园区全力抢占生物计算与智能医疗的产业制高点在今年4月举办的生物计算辅助药物研发平台交流会上 ↓↓↓ • 英矽智能展示生成式AI驱动的“算法-机器人实验室”协同平台，将靶点发现到临床转化效率提升了30%。 • 镁伽科技发布的“自动化+AI+生命科学”能力生态体系，实现实验流程智能化管理，大幅降低了人为操作误差与研发成本。这些AI技术的深度应用，不仅推动园区生物医药研发驶入“智能快车道”，更构建起从前沿技术研发到民生健康服务的完整智能生态，为产业高质量发展注入强劲的数字动能。 ▌文章来源：苏州工业园区发布责编：于嘉敏审核：任旭推荐阅读研发动态丨吉美瑞生：干细胞疗法实现60%肺纤维化面积逆转，近日已获批应用！研发动态丨FDA批准同心医疗BrioVAD进入确证性阶段临床研究研发动态丨信诺维：XNW28012治疗晚期转移性胰腺癌3期临床完成首例患者给药

上市批准抗体药物偶联物申请上市引进/卖出

2025-08-04

·Firstwordpharma

OrbiMed snags $1.9 billion for fifth healthcare fund amid 'challenging' market

OrbiMed raised $1.86 billion for its OrbiMed Royalty and Credit Opportunities Fund V on Monday. Via non-dilutive credit and royalty-based financings, the capital will be invested in biopharmaceutical companies, as well as those developing medical devices, diagnostics and tech-forward healthcare services.While the amount is smaller than OrbiMed's $4.3-billion Fund IV, closed in 2023, successfully bringing in funds during a punishing time for private healthcare companies is a positive move for the firm. "Equity markets have been challenging in recent years for biotech and life sciences companies," said OrbiMed General Partner Matthew Rizzo. "The OrbiMed platform is uniquely positioned to fund healthcare innovation and growth on a global basis."The close comes shortly after fellow venture firm Frazier Life Sciences raised $1.3 billion for its twelfth biotech fund, and AN Venture Partners closed its first fund at $200 million to invest in Japanese biopharma innovations. Some of OrbiMed's investments this year include AI-enabled drug design firm Insilico Medicines; shingles vaccine developer Curevo; RayThera and its portfolio of small molecules; and Renasant Bio, which is developing the first truly disease-modifying therapy for autosomal dominant polycystic kidney disease.

疫苗

100 项与英矽智能(香港)有限公司相关的药物交易

登录后查看更多信息

100 项与英矽智能(香港)有限公司相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

或

查看完整样例数据

管线布局

2025年08月21日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

药物发现

临床前

临床申请批准

临床1期

临床2期

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

Rentosertib ( TNIK )	特发性肺纤维化更多	临床2期
ISM-6331 ( TEAD )	晚期恶性实体瘤更多	临床1期
ISM-3412 ( Mat2A )	实体瘤更多	临床1期
ISM-5939 ( ENPP1 )	晚期恶性实体瘤更多	临床1期
ISM-8207 ( QPCTL )	晚期恶性实体瘤更多	临床1期